Sacituzumab govitecan: Additional Phase I/II data

Data from 56 evaluable patients with various types of gastrointestinal cancers in an open-label, U.S. Phase

Read the full 161 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE